Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth
The average time of dilation lasts three to eight hours
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Licences should enable potentially millions of people living in areas most impacted by HIV to access this innovative prevention medicine through low-cost generic manufacturers
Acquisitions have the potential to add at least $1 billion in sales by 2028
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
Subscribe To Our Newsletter & Stay Updated
